Earnings Call · Q3 FY2024·2024-10-30

Q3 24EPS +15.15%·Rev n/aQ2 24EPS +22.50%·Rev n/aQ1 24EPS +14.29%·Rev n/aQ4 23EPS +13.46%·Rev n/a⚠ consensus missing

NovoCure Ltd NVCR

Ingrid Goldberg — Investor Relations

Bill Doyle — Executive Chairman

Ashley Cordova — Chief Financial Officer (CFO)

Asaf Danziger — Chief Executive Officer (CEO)

+0.6%1d on move date+0.9% vs SPY3d−4.2%5d−1.6%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more NVCR calls or request research access.

More NVCR calls Browse calls Request research access